Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
- 9 February 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 51 (5), 1145-1149
- https://doi.org/10.1021/jm701272q
Abstract
The C-aryl glucoside 6 (dapagliflozin) was identified as a potent and selective hSGLT2 inhibitor which reduced blood glucose levels in a dose-dependent manner by as much as 55% in hyperglycemic streptozotocin (STZ) rats. These findings, combined with a favorable ADME profile, have prompted clinical evaluation of dapagliflozin for the treatment of type 2 diabetes.Keywords
This publication has 36 references indexed in Scilit:
- Diabetes and Mortality Following Acute Coronary SyndromesJAMA, 2007
- Metabolic SyndromeAmerican Journal of Cardiovascular Drugs, 2007
- Novel “Second-Generation” Approaches for the Control of Type 2 DiabetesJournal of Medicinal Chemistry, 2004
- Poor Control of Risk Factors for Vascular Disease Among Adults With Previously Diagnosed DiabetesJAMA, 2004
- Clinical importance of insulin secretion and its interaction with insulin resistance in the treatment of type 2 diabetes mellitus and its complicationsDiabetes/Metabolism Research and Reviews, 2001
- Chronic complications in diabetes mellitus.British Journal of Nutrition, 2000
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- IMPORTANCE OF GLUCOSE CONTROLMedical Clinics of North America, 1998
- Biophysical Characteristics of the Pig Kidney Na+/Glucose Cotransporter SGLT2 Reveal a Common Mechanism for SGLT1 and SGLT2Published by Elsevier BV ,1996
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993